4d Pharma PLC Clinical Update – Blautix IND

4D pharma plc (LON:DDDD), a pharmaceutical company leading the development of live biotherapeutics, has today announced that the Company has submitted, and the U.S. Food and Drug Administration (FDA) has cleared, an Investigational New Drug Application for Blautix, the Company’s live biotherapeutic for the treatment of Irritable Bowel Syndrome (IBS). Enrolment in the Phase 2 study is expected to commence in the second half of 2018.

The double-blind, placebo-controlled multicentre Phase 2 study will evaluate the efficacy and safety of Blautix in patients with IBS with constipation (IBS-C) and IBS with diarrhoea (IBS-D). 4D has consulted with the FDA on the design of the study. Up to 500 patients will receive either Blautix or placebo daily for 8 weeks. The primary endpoint will be the Overall Response rate, defined as the proportion of patients reporting an improvement in their weekly cohort-specific symptoms (abdominal pain and stool frequency or consistency) for at least 4 out of 8 weeks. A range of secondary efficacy endpoints will also be assessed, as well as the effects of Blautix on the gut microbiome.

Dr. Alex Stevenson, 4D Pharma Plc Chief Scientific Officer, commented: “We are delighted to advance Blautix into this important proof-of-concept study, which brings us another step closer to bringing a novel treatment regime to patients. Despite affecting up to 15% of the population, and a market forecast to be worth more than $2.5 billion by 2024*, IBS is poorly addressed with current therapies, which only target the symptoms of the disease rather than tackling the underlying causes. By targeting the microbiome, Blautix has the potential to make a real difference for patients and could represent a new era in the treatment of IBS.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    4d Pharma Plc

    More articles like this

    4d Pharma Plc

    4D pharma plc Clinical Update for Blautix Phase II Study

    4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, t0day announced the randomisation of the first patient in a Phase II clinical trial of Blautix in patients with Irritable Bowel Syndrome

    4d Pharma Plc

    IBS – 4 symptoms that extend beyond your stomach

    Unfortunately doctors still don’t know what causes irritable bowel syndrome (IBS) but they believe that a combination of problems can lead to the condition. They do , however, know that functional gastrointestinal (GI) disorders, such as

    4d Pharma Plc

    Food allergies: What a severe reaction feels like

    It was the mid-1990s. The incident involved a self-service counter and one bowl that contained hidden nuts. Adam was 10 years old. I was older, but still at school. I remember the nurse coming into my

    4d Pharma Plc

    What the gut knows

    The proximity of the anus to the genitals, Freud tells us, is the source of much if not all human neurosis. It’s fashionable to distance oneself from Freud these days, to say “I would not go

    4d Pharma Plc

    Are all probiotics equally good for your gut microbiome?

    The gut microbiome has become a key health focus, but not all yoghurts and probiotic supplements are born equally. QUESTION: Do all commercially available yogurts contain probiotics? Are all probiotics equally good for your gut microbiome or

    4d Pharma Plc

    Why more gut bacteria research is needed

    Do the bugs cohabiting our bodies influence disease risk, body weight or even manipulate our minds through the so-called gut-brain axis? A British Nutrition Foundation webinar finds promising therapeutic potential. But, we need a better understanding

    4d Pharma Plc

    4D pharma plc Positive Data From Phase 1b Study of Thetanix

    Dr. Alex Stevenson, 4D’s Chief Scientific Officer, said.“These promising results add to the growing body of evidence on the efficacy of Thetanix, further reinforcing its potential as a novel treatment for Crohn’s disease.  Achieving the primary

    4d Pharma Plc

    Is your microbiome making you sick?

    Our gut bacteria can play a role in everything from sleep to IBS and how we deal with stress, and we are finally working out how to use them to improve our health. In the last

    4d Pharma Plc

    A Beginner’s Guide to Gut Health

    Why gut health is critical Given the intimate relationship between our gut and your brain—the two brains if you will—it makes perfect sense that we would want to ensure we are providing the best support and